부산대학교 도서관

Abstract Introduction This multicenter, retrospective study aimed to evaluate the efficiency, retention, safety, and tolerability of brivaracetam (BRV) in children and adolescents with focal epilepsy. Methods All patients aged ≤ 17 years with focal epilepsy who started BRV in 2016 and 2017 were analyzed. Results Thirty-four patients (mean age: 12.2 years, range: 3–17 years, 56% female) were treated with BRV for 25 days to 24 months, with a total exposure time of 19.7 years. Overnight switch from levetiracetam (LEV) to BRV was performed in 20 patients at a median ratio of 10:1. Retention rate was 97% at three months, with only one patient reporting a discontinuation of BRV treatment. Further dropouts were reported in one patient after seven months and in two patients after one year of treatment, respectively. The median length of exposure to BRV was 180 days. Efficacy at three months was 47% (50% responder rate), with 10 patients (29%) reporting seizure freedom. A long-term 50% responder rate was present in 12 patients [35%; four patients seizure-free (12%)] for more than six months and in seven patients (21%; no seizure-free patients) for more than 12 months. Treatment-emergent adverse events were observed in 12% of patients, with the most common being sedation, somnolence, loss or gain of appetite, and psychobehavioral adverse events. Conclusions Use of BRV in children and adolescents seems to be safe and well-tolerated. The results with 50% responder rate of 47% are consistent with those from randomized controlled trials and postmarketing studies in adults. An immediate switch from LEV to BRV at a ratio of 10:1 is feasible. The occurrence of psychobehavioral adverse events seems less prominent than under LEV and a switch to BRV can be considered in patients with LEV-induced adverse events. Highlights • Postmarketing data in 34 children with focal epilepsies and brivaracetam treatment • 50% responder rates of 47% (29% seizure-free) for three months • Retention rate of 97% at three months and median exposure of 180 days • Immediate switch from levetiracetam to brivaracetam at 10:1 ratio is feasible without titration. • The main adverse events are sedation, somnolence, and behavioral adverse events. [ABSTRACT FROM AUTHOR]